The Pharma Data

JANUARY 12, 2021

Select pipeline updates, since third quarter results were reported in October 2020 , regarding promising individual programs and broader platform opportunities include: Completion of enrollment in the Phase 3 trial of ULTOMIRIS in gMG, with top-line data expected in the second half of 2021. Securities Act of 1933, as amended.

Containment 52

Containment Development Sales Production 52

XTalks

FEBRUARY 8, 2024

According to AstraZeneca, the drug had strong demand across all of its approved indications and was further supported by recent guideline updates from cardiology societies. The efficacy and safety of Rybelsus in reducing blood sugar in patients with type 2 diabetes were investigated in various clinical trials. billion ($657 million).

Sales 52

Sales Insulin FDA Approval Drugs 52

The Pharma Data

NOVEMBER 4, 2020

Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. Common adverse reactions in the cardiovascular outcomes trial (incidence ?3% commercial team. “In

Sales 40

Sales Production Cardiology Marketing 40

XTalks

APRIL 15, 2021

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. Heart failure affects about 6.2 As heart rate increases, so too does the likelihood of experiencing ischemic episodes.

Development 98

Development Drugs Genome Genomics 98

XTalks

JANUARY 19, 2024

Radiobiological and Clinical Considerations from CRO and Emerging Biotech Radiopharmaceuticals are medicinal formulations containing radioisotopes that are used in the field of nuclear medicine primarily for the diagnosis and treatment of various diseases, particularly cancer. In addition, the cascades can also contain beta emissions.

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

OCTOBER 14, 2020

Michael Felker, MD, MHS, FACC, FAHA, FHFSA is Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine. He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology. About Dr. Udelson James E.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40

The Pharma Data

NOVEMBER 16, 2020

The “polypill” containing three generic blood pressure medications and a statin dramatically reduced the risk of heart-related illness in people with no prior history of heart problems, according to clinical trial results. MONDAY, Nov. If it’s more convenient together, why not?” ” Yusuf said.

Doctors 52

Doctors Doctor Cardiology Pharma Companies 52

The Pharma Data

SEPTEMBER 15, 2020

Limited blinded tolerability data from the ongoing Phase 3 trial, confirming the mostly mild to moderate tolerability profile as was observed in Phase 1. In the blinded data presented, 50% of trial participants received placebo and 50% received BNT162b2. A Phase 3 trial is ongoing. Protease Inhibitor Program. Rare Disease.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

pharmaphorum

FEBRUARY 26, 2021

The company has also faced claims that it did not adequately communicate the risks of its opioid painkillers in its marketing, contributing to the US’ ‘opioid epidemic’, and that its talc products could contain small amounts of asbestos and lead to cancer.

Sales 125

Sales Production Pharma Companies Marketing 125

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. Pfizer’s total global revenue from Paxlovid was $18.93 billion in 2022. and $16,382.51 billion ($1.17

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

OCTOBER 29, 2020

In the third quarter, we further progressed our LEAD-EXPAND-DIVERSIFY strategy with multiple regulatory approvals, the initiation of new Phase 3 trials and the integration of the Portola team,” said Ludwig Hantson , Ph.D., Chief Executive Officer of Alexion. ” Third Quarter 2020 Financial Highlights.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

The Pharma Data

APRIL 26, 2021

At present, drug development operations are continuing with manageable disruptions (see the Innovation Review Section of the Condensed Interim Financial Report for further information), with our range of digital technologies allowing us to proactively manage our clinical trials portfolio and rapidly mitigate any disruptions. Cosentyx. .

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

MAY 13, 2021

Fructose Containing Sugars at Normal Levels of Consumption Do Not Effect Adversely Components of the Metabolic Syndrome and Risk Factors for Cardiovascular Disease. based weight loss intervention in adults with obesity: A randomized clinical trial. Fructose-containing sugars, blood pressure, and cardiometabolic risk: a critical review.

Insulin 52

Insulin Production Hormones Medicine 52